The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.
Filippo G. De Braud
Research Funding - Boehringer Ingelheim
Stefano Cascinu
Consultant or Advisory Role - Amgen; Pfizer; Roche
Research Funding - Merck
Gianluca Spitaleri
No relevant relationships to disclose
Korinna Pilz
Employment or Leadership Position - Boehringer Ingelheim
Laura Clementi
Employment or Leadership Position - Boehringer Ingelheim
Dan Liu
Employment or Leadership Position - Boehringer Ingelheim
Patricia Glomb
Employment or Leadership Position - Boehringer Ingelheim
Tommaso De Pas
No relevant relationships to disclose